InsiderTrades.com logo
Otis W. Brawley net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Otis Brawley Biography and Net Worth

Director of Lyell Immunopharma

Otis Brawley, M.D., has served as a member of our board of directors since April 2021. Dr. Brawley has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019 and a member the board of directors of PDS Biotechnology Corporation, a publicly traded biotechnology company, since November 2020, Incyte Corporation since September 2021 and Agilent Technologies since November 2021. From April 2007 to December 2018, he served as the Chief Medical and Scientific Officer of American Cancer Society. From January 2002 to August 2007, he was director of the Georgia Cancer Center at Grady Memorial Hospital. From April 2001 to December 2018, he served as a professor of hematology, oncology, medicine and epidemiology at Emory University. Dr. Brawley received an M.D. from the University of Chicago, Pritzker School of Medicine and a B.S. in Chemistry from the University of Chicago. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the National Cancer Institute. He is board certified in internal medicine and medical oncology.

What is Otis W. Brawley's net worth?

The estimated net worth of Otis W. Brawley is at least $45.37 thousand as of March 31st, 2025. Brawley owns 1,782 shares of Lyell Immunopharma stock worth more than $45,370 as of December 4th. This net worth estimate does not reflect any other assets that Brawley may own. Learn More about Otis W. Brawley's net worth.

How do I contact Otis W. Brawley?

The corporate mailing address for Brawley and other Lyell Immunopharma executives is , , . Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on Otis W. Brawley's contact information.

Has Otis W. Brawley been buying or selling shares of Lyell Immunopharma?

Otis W. Brawley has not been actively trading shares of Lyell Immunopharma in the last ninety days. Most recently, on Monday, March 31st, Otis W. Brawley bought 1,782 shares of Lyell Immunopharma stock. The stock was acquired at an average cost of $11.20 per share, with a total value of $19,958.40. Following the completion of the transaction, the director now directly owns 1,782 shares of the company's stock, valued at $19,958.40. Learn More on Otis W. Brawley's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Otis Brawley (Director), Otis Brawley (Director), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), and Lynn Seely (CEO). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, Lyell Immunopharma insiders bought shares 5 times. They purchased a total of 38,432 shares worth more than $449,508.40. In the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,400 shares worth more than $30,063.50. The most recent insider tranaction occured on November, 10th when CEO Lynn Seely sold 412 shares worth more than $6,637.32. Insiders at Lyell Immunopharma own 22.3% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 11/10/2025.

Otis W. Brawley Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2025Buy1,782$11.20$19,958.401,782View SEC Filing Icon  
See Full Table

Otis W. Brawley Buying and Selling Activity at Lyell Immunopharma

This chart shows Otis W Brawley's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $25.46
Low: $21.39
High: $25.59

50 Day Range

MA: $18.18
Low: $12.83
High: $25.46

2 Week Range

Now: $25.46
Low: $7.65
High: $25.59

Volume

93,527 shs

Average Volume

39,594 shs

Market Capitalization

$540.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A